Earnings summaries and quarterly performance for KalVista Pharmaceuticals.
Executive leadership at KalVista Pharmaceuticals.
Benjamin L. Palleiko
Detailed
Chief Executive Officer
CEO
Bilal Arif
Detailed
Chief Operating Officer
Brian Piekos
Detailed
Chief Financial Officer
Christopher M. Yea
Detailed
Chief Development Officer
Linea Aspesi
Detailed
Chief People Officer
Nicole Sweeny
Detailed
Chief Commercial Officer
Paul K. Audhya
Detailed
Chief Medical Officer
Board of directors at KalVista Pharmaceuticals.
Research analysts who have asked questions during KalVista Pharmaceuticals earnings calls.
Maury Raycroft
Jefferies
5 questions for KALV
Also covers: ABEO, ALNY, ARWR +11 more
Paul Matteis
Stifel
3 questions for KALV
Also covers: ABOS, ACAD, ALKS +11 more
Pete Stavropoulos
Cantor Fitzgerald
3 questions for KALV
Also covers: ABOS, ALEC, ARCT +7 more
Serge Belanger
Needham & Company
3 questions for KALV
Also covers: AMPH, ARQT, BCRX +12 more
Stacy Ku
TD Cowen
3 questions for KALV
Also covers: AUPH, BCRX, RVNC +3 more
Tazeen Ahmad
Bank of America
3 questions for KALV
Also covers: ACAD, ALNY, APLS +20 more
Catherine
Citizens
2 questions for KALV
Also covers: OCUL
Debanjana Chatterjee
JonesTrading Institutional Services
2 questions for KALV
Also covers: ABSI, CLSD, EYPT +2 more
Devanjana Chatterjee
Jones
2 questions for KALV
Joe Schwartz
Leerink Partners
2 questions for KALV
Also covers: BMRN, PTGX, WVE
John Wallman
Citizens Bank
2 questions for KALV
Matthew
Stifel
2 questions for KALV
Sergey Balintur
Needham & Company
2 questions for KALV
Stacy Koo
TV Co
2 questions for KALV
William Dubin
Leerink
2 questions for KALV
Catherine Okoukoni
Citizens JMP
1 question for KALV
Also covers: ALT, CRNX, MDGL +2 more
Will Soghikian
Leerink Partners
1 question for KALV
Also covers: AUPH, RARE, TVTX
Recent press releases and 8-K filings for KALV.
KalVista Provides Update on Ekterly Launch and Market Penetration
KALV
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- KalVista Pharmaceuticals launched Ekterly, the first oral therapy for on-demand treatment of acute HAE attacks, in July following FDA approval.
- The company has seen rapid uptake, with over 1,000 patients on therapy, representing comfortably over 10% of the marketplace.
- KalVista reported $13.7 million in revenue last quarter, primarily reflecting actual end-user demand, with severe disease patients showing high refill frequency (e.g., three to four weeks).
- The company anticipates maintaining market leadership despite upcoming competitor data, citing Ekterly's early market entry, high patient satisfaction, and the distinct design of its clinical trials.
- International expansion includes a first shipment to Germany in October, with planned launches in the U.K. in H1 2026 and Japan in Q1 2026, though XUS markets are expected to price at a fraction of U.S. pricing (e.g., 20% of U.S. price).
Nov 19, 2025, 1:30 PM
KalVista Pharmaceuticals Provides Update on EKTERLY Launch and Commercialization
KALV
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- KalVista Pharmaceuticals launched EKTERLY, an oral therapy for acute HAE attacks, in July following FDA approval, marking a substantial advance in treatment.
- As of November 2025, over 1,000 patients are on EKTERLY therapy, representing 12-13% of the marketplace, with rapid uptake.
- The company reported $13.7 million in revenue last quarter, primarily driven by end-user demand for EKTERLY.
- International expansion plans include the first shipment to Germany in October, with launches expected in the U.K. in H1 2026 and Japan in Q1 2026; XUS markets are projected to contribute 20% of global revenue long-term.
- KalVista does not anticipate upcoming Pharvaris Phase 3 data to impact EKTERLY's commercial trajectory due to significant differences in study design and EKTERLY's established market position.
Nov 19, 2025, 1:30 PM
KalVista Pharmaceuticals Discusses EKTERLY Launch and Market Trajectory
KALV
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- KalVista Pharmaceuticals launched EKTERLY, an oral therapy for the on-demand treatment of acute attacks of HAE, in July after FDA approval.
- As of November 19, 2025, over 1,000 patients are on therapy, representing 12%-13% of the marketplace, with 937 start forms reported earlier, indicating extraordinarily fast uptake.
- The company reported $13.7 million in revenue for the last quarter, primarily reflecting actual end-user demand for EKTERLY.
- Refills are evolving, with severe disease patients (15%-20% of the total patient population) refilling at a high frequency of three to four weeks, often with multiple cartons.
- International launches include the first shipment to Germany in October, with planned launches in the U.K. in the first half of 2026 and Japan in the first quarter of 2026.
Nov 19, 2025, 1:30 PM
KalVista Pharmaceuticals Reports Strong Initial Commercial Performance for EKTERLY
KALV
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- KalVista Pharmaceuticals reported its first full commercial quarter for EKTERLY, the first and only oral therapy for HAE attacks, following its approval on July 3 and launch on July 7.
- The launch has demonstrated strong uptake, with 10%-12% of patients converting to EKTERLY in less than four months, resulting in revenues meaningfully exceeding expectations.
- The company is consistently adding approximately 200-220 new patients per month, with early adopters largely being high-attack rate patients who show higher refill rates.
- Payer coverage is developing as anticipated, with major formularies expected by early 2026, and international expansion is underway, including a successful launch in Germany.
- KalVista plans to grow into a leading rare disease commercial entity, with an NDA filing for the pediatrics indication anticipated in Q3 next year.
Nov 12, 2025, 1:40 PM
KalVista Pharmaceuticals Discusses Strong EKTERLY Launch and Global Expansion
KALV
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- EKTERLY, the first oral therapy for HAE attacks, was approved on July 3 and launched on July 7, 2025. Within less than four months, 10%-12% of patients have already converted to EKTERLY.
- The company reported its first full quarter as a commercial entity, with revenues meaningfully beyond expectations, primarily driven by actual patient demand.
- Payer coverage is progressing as anticipated, with smaller payers adopting policies faster, and the vast majority of prescriptions in the third quarter were medical exceptions.
- Half of the patients switching to EKTERLY self-reported two or more attacks per month, validating the company's theory about a high-attack rate population that is highly receptive to the drug.
- KalVista launched EKTERLY in Germany last month and plans further European expansion and global partnerships, aiming to become a leading rare disease commercial entity.
Nov 12, 2025, 1:40 PM
KalVista Pharmaceuticals Reports Strong Initial EKTERLY Launch Performance
KALV
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- KalVista Pharmaceuticals successfully launched EKTERLY, the first and only oral therapy for HAE attacks, on July 7, and reported its first full commercial quarter with revenues "meaningfully beyond where people thought they would".
- In less than four months, 10%-12% of patients have already converted to EKTERLY, with about half of these patients self-reporting two or more attacks a month, indicating strong uptake among high-need individuals.
- Payer coverage is progressing as anticipated, with smaller formularies adopting policies faster, while larger payers are expected to finalize policies by early 2026; the majority of prescriptions in the first commercial quarter were obtained via medical exception.
- The company has begun international expansion, launching EKTERLY in Germany last month with sales exceeding expectations, and plans to launch in the UK next year, though ex-US markets are expected to contribute about 20% of total revenue with significantly lower pricing power compared to the US.
Nov 12, 2025, 1:40 PM
KalVista Pharmaceuticals Reports Q3 2025 EKTERLY Sales and Launch Progress
KALV
Earnings
Product Launch
Guidance Update
- KalVista Pharmaceuticals reported $13.7 million in EKTERLY sales for the launch period through September 30.
- The U.S. launch of EKTERLY has seen strong early adoption with 937 start forms and 423 unique prescribers in less than four months, while international launches are progressing in Germany, the U.K., and Japan.
- The company is now fully financed through profitability following a recent convertible note offering.
- Total operating expenses for Q3 2025 were $59.7 million, comprising $12 million in R&D and $46.5 million in SG&A.
- Positive clinical data from the KONFIDENT-KID trial for children aged 2-11 and high patient satisfaction from the KONFIDENT-S trial were highlighted, with a pediatric NDA submission for EKTERLY anticipated in Q3 2026.
Nov 11, 2025, 1:30 PM
KalVista Pharmaceuticals Reports Q3 2025 Financial Results and Provides EKTERLY Launch Updates
KALV
Earnings
Product Launch
Guidance Update
- KalVista Pharmaceuticals reported EKTERLY sales of $13.7 million for the launch period through September 30.
- Total operating expenses for the three-month period ending September 30 were $59.7 million, consisting of approximately $12 million in R&D expenses and $46.5 million in SG&A expenses.
- The company launched EKTERLY in Germany in mid-October and plans launches in the U.K. in first-half 2026 and Japan in Q1 2026.
- An NDA for pediatrics for sebetralstat is expected to be submitted in Q3 2026.
- The company's cash position is sufficient to fund operations through profitability due to recent convertible note financing.
Nov 11, 2025, 1:30 PM
KalVista Pharmaceuticals Reports Strong Initial EKTERLY Launch Performance and Global Expansion in Q3 2025
KALV
Earnings
Product Launch
New Projects/Investments
- KalVista Pharmaceuticals announced $13.7 million in EKTERLY sales for the launch period through September 30, 2025, with 937 start forms received in less than four months, indicating strong early adoption and demand in the U.S. market.
- The company is expanding EKTERLY's global presence, with a launch underway in Germany, recent approval in Australia, and planned launches in the U.K. (first-half 2026) and Japan (Q1 2026).
- For Q3 2025, total operating expenses were $59.7 million, comprising $12 million in R&D and $46.5 million in SG&A, and the company confirmed it is fully financed through profitability after a recent convertible note offering.
- Patient satisfaction with EKTERLY is high, with 84% of attacks treated rated as satisfied to extremely satisfied by participants who switched from injectable therapies, supporting its role as a foundational HAE treatment.
Nov 11, 2025, 1:30 PM
KalVista Pharmaceuticals Reports Strong Q3 Earnings and EKTERLY Launch Success
KALV
Earnings
Product Launch
Debt Issuance
- KalVista Pharmaceuticals reported strong Q3 results, with its new oral HAE treatment, EKTERLY, generating $13.7 million in net product revenue from 937 patient starts and 423 unique prescribers.
- The company's revenue of $13.69 million and earnings per share of ($0.92) both surpassed analyst expectations, despite a net loss of $49.5 million for the quarter.
- KalVista is expanding EKTERLY's market presence globally and secured a $144 million convertible note offering to support financial stability and ongoing clinical progress, including the fully recruited KONFIDENT-KID trial for pediatric HAE patients.
- Investor optimism was reflected in an 11.29% after-hours stock gain following the earnings release.
Nov 11, 2025, 1:02 AM
Quarterly earnings call transcripts for KalVista Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more